Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-TIL052A in advanced cervical cancer
NCT05475847Phase 1Unknown
- Sponsor
- Fudan University
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor infiltrating lymphocytes C-TIL052A in Cervical Cancer (CC), sponsored by Fudan University. Primary endpoint: Adverse Events up to 12 months. Status: unknown.
02
Drugs
autologous tumor infiltrating lymphocytes C-TIL052A
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05475847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475847.